he Seattle biotech Omeros (OMER) has reported sharply lower sales of its cataract surgery drug in the fourth quarter after losing favorable Medicare reimbursement at the end of last year.

Lacking a reimbursement fix, Omeros offered a bleak sales outlook for this year for the drug, Omidria, raising the risk that the company might end up in default on a business loan.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.